ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Randomized Trial"

  • Abstract Number: L08 • ACR Convergence 2020

    Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)

    Thomas MacDonald1, Isla Mackenzie1, George Nuki2 and Ian Ford3, 1University of Dundee, Dundee, Scotland, United Kingdom, 2University of Edinburgh, Edinburgh, Scotland, United Kingdom, 3University of Glasgow, Glasgow, Scotland, United Kingdom

    Background/Purpose: Febuxostat and allopurinol are uric acid lowering agents. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency (EMA) recommended a post-authorization…
  • Abstract Number: L09 • ACR Convergence 2020

    A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)

    Dinesh Khanna1, Christopher Denton2, Daniel Furst3, Maureen Mayes4, Marco Matucci-Cerinic5, Vanessa Smith6, Dick de Vries7, Liesbeth Deberdt8, Pieter‑Jan Stiers8, Niyati Prasad8 and Sohail Ahmed9, 1University of Michigan, Ann Arbor, MI, 2Royal Free Hospital, University College London, London, United Kingdom, 3David Geffen School of Medicine at UCLA, Los Angeles, CA, 4University of Texas Health Science Center at Houston, Houston, TX, 5Università degli Studi di Firenze, Firenze, Italy, 6Ghent University Hospital, Ghent, Belgium, 7Galapagos BV, Leiden, Netherlands, 8Galapagos NV, Mechelen, Belgium, 9Ahmed Science Medicine, Basel, Switzerland

    Background/Purpose: There is a high unmet need for systemic sclerosis (SSc) treatments. Ziritaxestat (ziri; GLPG1690) is an autotaxin inhibitor with a novel mechanism of action.…
  • Abstract Number: L11 • ACR Convergence 2020

    Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Atul Deodhar1, Paula Sliwinska-Stanczyk2, Huji Xu3, Xenofon Baraliakos4, Lianne Gensler5, Dona Fleishaker6, Lisy Wang6, Joseph Wu6, Sujatha Menon6, Cunshan Wang6, Oluwaseyi Dina7, Lara Fallon8, Keith S Kanik6 and Désirée van der Heijde9, 1Oregon Health & Science University, Portland, OR, 2Reumatika Centrum Reumatologii, Warszawa, Poland, 3Shanghai Changzheng Hospital, Shanghai, China (People's Republic), 4Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Bochum, Germany, 5University of California San Francisco, San Francisco, CA, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, New York, NY, 8Pfizer Inc, Montreal, QC, Canada, 9Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for the treatment of adult patients (pts) with AS.Methods: This Phase 3, randomized, double-blind…
  • Abstract Number: 0200 • ACR Convergence 2020

    Predictors of Durable Clinical Response to Tofacitinib 11 Mg Once Daily with or Without Methotrexate in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Data from a Phase 3b/4 Methotrexate Withdrawal Study

    Kunihiro Yamaoka1, Stanley B Cohen2, Naonobu Sugiyama3, Harry Shi4, Jose L Rivas5, Annette Diehl4 and Josef Smolen6, 1Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, 2Metroplex Clinical Research Center, Dallas, TX, 3Pfizer Japan Inc, Tokyo, Japan, 4Pfizer Inc, Collegeville, PA, 5Pfizer SLU, Madrid, Spain, 6Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria

    Background/Purpose: ORAL Shift, a global Phase 3b/4 non-inferiority study, demonstrated sustained efficacy/safety of tofacitinib modified-release (MR) 11 mg QD following MTX withdrawal in patients (pts)…
  • Abstract Number: 0962 • ACR Convergence 2020

    Efficacy of Clomipramine for Chronic Lumbar Radicular Pain a Randomized Clinical Trial

    Saloua Afilal1, Safaa Fellous1, Ilham Aachari1, Redouane Abouqal2, Ihsane Hmamouchi3, Nada Alami1, Latifa Tahiri1, Hanan Rkain1, Najia Hajjaj-Hassouni4 and Fadoua Allali1, 1Rheumatology B Department, El Ayachi Hospital, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco., Rabat, Morocco, 2Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco., Rabat, Morocco, 3Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, Rabat, Morocco, 4Health Sciences College, International University of Rabat (UIR), Rabat, Morocco

    Background/Purpose: Lumbar radicular pain is the most common chronic neuropathic pain syndrome. Antidepressants are highly recommended for neuropathic pain, but there is no evidence for…
  • Abstract Number: 1486 • ACR Convergence 2020

    Long-term Efficacy and Safety of Intra-articular Sprifermin in Patients with Knee Osteoarthritis: Results from the 5-Year Forward Study

    Felix Eckstein1, Marc Hochberg2, Hans Guehring3, Flavie Moreau4, Victor Ona4, Asger Bihlet5, Inger Byrjalsen5, Jeppe Andersen5, Benjamin Daelken3, Oliver Guenther3, Christoph Ladel3, Martin Michaelis3 and Philip G Conaghan6, 1Paracelsus Medical University, Salzburg, Austria, 2University of Maryland School of Medicine, Baltimore, MD, 3Merck KGaA, Darmstadt, Germany, 4EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 5Nordic Bioscience, Herlev, Denmark, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom

    Background/Purpose: The 5-year Phase II FORWARD study assessed the efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin (recombinant human fibroblast growth factor…
  • Abstract Number: 0220 • ACR Convergence 2020

    Impact of Concomitant Glucocorticoids on the Clinical Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: An Ad Hoc Analysis of Data from Three Phase 3 Studies

    Bernard Combe1, Frank Buttgereit2, Andrew Östör3, Ricardo Xavier4, Alain Saraux5, Capucine Daridon6, Kirsten Famulla7, Yanna Song8, Ivan Lagunes-Galindo9 and Gerd Burmester10, 1University of Montpellier, Montpellier, France, 2Charité University Medicine, Berlin, Germany, 3Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, 4Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Rio Grande do Sul, Brazil, 5Department of Rheumatology, UBO, CHU, INSERM 1227 (LBAI), Brest, France, 6AbbVie France, Rungis, France, 7AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 8AbbVie Inc., North Chicago,, IL, 9AbbVie Inc., North Chicago, IL, 10Charité University Hospital Berlin, Berlin, Germany

    Background/Purpose: Glucocorticoid (GC) therapy has strong anti-inflammatory effects and helps slow radiographic progression in RA1; however, GCs can be associated with adverse events (AEs) such…
  • Abstract Number: 0986 • ACR Convergence 2020

    BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus

    Victoria Werth1, Richard Furie2, Juanita Romero-Díaz3, Sandra Navarra4, Kenneth Kalunian5, Ronald van Vollenhoven6, Filippa Nyberg7, Benjamin Kaffenberger8, Saira Sheikh9, Goran Radunovic10, Xiaobi Huang11, Hua Carroll12, Francois Gaudreault12, Adam Meyers11, Catherine Barbey13, Cristina Musselli11 and Nathalie Franchimont11, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 2Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 3Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 4University of Santo Tomas, Manila, Philippines, 5University of California San Diego, La Jolla, CA, 6Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 7Karolinska University Hospital, Stockholm, Sweden, 8Ohio State University, Columbus, OH, 9Division of Rheumatology, Allergy and Immunology, University of North Carolina, Chapel Hill, NC, 10Institute of Rheumatology, University of Belgrade, Belgrade, Serbia, 11Biogen, Cambridge, MA, 12Biogen, Cambridge, 13Biogen, Baar, Switzerland

    Background/Purpose: No approved targeted therapies have been developed for cutaneous lupus erythematosus (CLE), a disfiguring autoimmune disease that severely impairs quality of life.1 BIIB059 is…
  • Abstract Number: 1633 • ACR Convergence 2020

    A Randomized, Double-Blind, Placebo-Controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease

    Laura Schanberg1, Peter Nigrovic2, Ashley Cooper3, Winn Chatham4, Shoghik Akoghlanian5, Namrata Singh6, C. Egla Rabinovich7, Akaluck Thatayatikom8, Alysha Taxter9, Jonathan Hausmann10, Milan Zdravkovic11, Sven Ohlman11, Henrik Andersson11, Susanna Cederholm11, Gunilla Huledal11, Rayfel Schneider12 and Fabrizio De Benedetti13, 1Duke University Medical Center, Durham, NC, 2Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, 3Children's Mercy Kansas City, Kansas City, MO, 4University of Alabama at Birmingham, Birmingham, AL, 5Nationwide Children’s Hospital, Columbus, 6University of Washington, Bellevue, WA, 7Duke University Hospital, Durham, NC, 8Department of Pediatrics, University of Florida, Gainesville, FL, 9Wake Forest Baptist Medical Center, Winston-Salem, 10Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 11Sobi, Stockholm, Sweden, 12University of Toronto, The Hospital for Sick Children, Toronto, Canada, 13Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy

    Background/Purpose: Still’s disease, including both systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still’s disease (AOSD), is a rare systemic auto-inflammatory disorder associated with an activated…
  • Abstract Number: 0228 • ACR Convergence 2020

    Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study

    Eduardo Mysler1, Yoshiya Tanaka2, Arthur Kavanaugh3, Daniel Aletaha4, Peter Taylor5, In-Ho Song6, Tim Shaw6, Yanna Song7, Ryan DeMasi6, Mira Ali6 and Roy Fleischmann8, 1Organización Medica de Investigación, Buenos Aires, Argentina, 2The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 3Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, 4Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, 5Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 6AbbVie Inc., North Chicago, IL, 7AbbVie Inc., North Chicago,, IL, 8Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: In the randomized, double-blinded, Phase 3 SELECT-COMPARE study, upadacitinib (UPA) + MTX demonstrated greater clinical and functional responses vs adalimumab (ADA) + MTX in…
  • Abstract Number: 0987 • ACR Convergence 2020

    Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study

    Joan Merrill1, Victoria Werth2, Richard Furie3, Ronald van Vollenhoven4, Milan Petronijevic5, Benito Velasco Zamora6, Maria Majdan7, Fedra Irazoque-Palazuelos8, Michael Weiswasser9, Shimon Korish9, Peter Schafer9, Zhaohui Liu9, Allison Gaudy9, Nataliya Agafonova9 and Nikolay Delev9, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 3Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 4Amsterdam University Medical Centers, Amsterdam, Netherlands, 5Military Medical Academy, Belgrade, Serbia, 6Instituto CER S.A., Buenos Aires, Argentina, 7Medical University of Lublin and Samodzielny Publicnzy Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland, 8Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, 9Bristol Myers Squibb, Princeton

    Background/Purpose: Iberdomide is a high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors linked to the genetic…
  • Abstract Number: 1842 • ACR Convergence 2020

    Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus: Post Hoc Analyses of Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial

    Anca Askanase1, George Wan2, Mary Panaccio2, Enxu Zhao2, Julie Zhu2, Roman Bilyk2 and Richard Furie3, 1Columbia University College of Physicians and Surgeons, New York, NY, 2Mallinckrodt Pharmaceuticals, Bedminster, NJ, 3Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY

    Background/Purpose: Repository corticotropin injection (RCI, Mallinckrodt Pharmaceuticals) is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides approved for the treatment…
  • Abstract Number: 0369 • ACR Convergence 2020

    Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs

    Atul Deodhar1, Xenofon Baraliakos2, Iain McInnes3, Kurt de Vlam4, Louis Bessette5, Anna Maniccia6, Ralph Lippe7, Christopher Saffore6, Tianming Gao6, In-Ho Song6 and Andrew Östör8, 1Oregon Health & Science University, Portland, OR, 2Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, 3Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 4Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, 5Laval University, Quebec, Canada, 6AbbVie Inc., North Chicago, IL, 7AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 8Cabrini Medical Center, Monash University, Malvern, Victoria, Australia

    Background/Purpose: Pain is a debilitating symptom of ankylosing spondylitis (AS) and negatively impacts patient (pt) lives. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor engineered for…
  • Abstract Number: 0989 • ACR Convergence 2020

    Withdrawal of MMF Is Safe in Quiescent Renal and Non-Renal SLE: Results from a Multi-Center Randomized Trial

    Eliza Chakravarty1, Tammy Utset2, Diane Kamen3, Gabriel Contreras4, W. Joseph McCune5, Kenneth Kalunian6, Cynthia Aranow7, Megan Clowse8, Elena Massarotti9, Ellen Goldmuntz10, Jessica Springer10, Lynette Keyes-Elstein11, Bill Barry11, Ashley Pinckney11 and Judith James12, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Chicago, Chicago, IN, 3Medical University of South Carolina, Charleston, SC, 4University of Miami Miller School of Medicine, Miami, 5University of Michigan, Ann Arbor, MI, 6University of California San Diego, La Jolla, CA, 7Feinstein Institutes for Medical Research, Manhasset, NY, 8Duke University, Chapel Hill, NC, 9Brigham and Women's hospital, Boston, MA, 10NIH/NIAID, Rockville, MD, 11Rho, Durham, NC, 12Oklahoma Medical Research Foundation, Oklahoma City

    Background/Purpose: Mycophenolate Mofetil (MMF) is standard of care therapy for long term treatment of lupus nephritis and other manifestations of SLE.  However, it is associated…
  • Abstract Number: 1843 • ACR Convergence 2020

    Integrated Efficacy of the AURORA 1 and AURA-LV Trials Confirms Voclosporin Rapid Proteinurea Reduction in the Presence of Low-Dose Steroids

    Ellen M Ginzler1, Joshua Kaplan2, Laura Lisk3, Ray Federico4, Neil Solomons5 and Robert Huizinga5, 1SUNY Downstate Health Sciences University, Brooklyn, 2Rutgers University, New Brunswick, NJ, 3Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, 4Aurinia Pharmaceuticals, Inc., Victoria, Canada, 5Aurinia Pharmaceuticals, Victoria, BC, Canada

    Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor (CNI) with a favorable metabolic profile and a consistent predictable dose response potentially eliminating the need for…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.